Cullinan Therapeutics, Inc. Common Stock CGEM
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $35.00 (+107.5% upside)
Key Stats
- Today's Range
- $16.78 – $21.67
- 50-Day Range
- $16.00 – $23.19
- 52-Week Range
- $5.68 – $23.19
- Volume
- 2.60 million shs
- Average Volume
- 951K shs
- Market Cap
- $1.39 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.33
- Price / Sales
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.25
Financials (TTM)
- Revenue
- —
- Net Income
- $-204,688,000
- Net Margin
- —
- Return on Equity
- -63.62%
- Debt-to-Equity
- —
About Cullinan Therapeutics, Inc. Common Stock
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Related Stocks
Compare head-to-head: CGEM vs AMGN·CGEM vs MRNA·CGEM vs HALO·CGEM vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.